A detailed history of Hallmark Capital Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Hallmark Capital Management Inc holds 27,189 shares of ABBV stock, worth $4.77 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
27,189
Previous 28,553 4.78%
Holding current value
$4.77 Million
Previous $4.9 Million 9.64%
% of portfolio
0.41%
Previous 0.4%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$163.84 - $199.33 $223,477 - $271,886
-1,364 Reduced 4.78%
27,189 $5.37 Million
Q2 2024

Aug 08, 2024

SELL
$154.79 - $180.76 $339,764 - $396,768
-2,195 Reduced 7.14%
28,553 $4.9 Million
Q1 2024

May 03, 2024

SELL
$159.82 - $182.1 $292,310 - $333,060
-1,829 Reduced 5.61%
30,748 $5.6 Million
Q4 2023

Feb 07, 2024

SELL
$137.6 - $154.97 $115,721 - $130,329
-841 Reduced 2.52%
32,577 $5.05 Million
Q3 2023

Nov 09, 2023

SELL
$133.59 - $154.65 $202,388 - $234,294
-1,515 Reduced 4.34%
33,418 $4.98 Million
Q2 2023

Jul 28, 2023

SELL
$132.51 - $164.9 $194,392 - $241,908
-1,467 Reduced 4.03%
34,933 $4.71 Million
Q1 2023

May 03, 2023

SELL
$144.61 - $166.54 $138,680 - $159,711
-959 Reduced 2.57%
36,400 $5.8 Million
Q4 2022

Feb 01, 2023

SELL
$138.31 - $165.87 $204,145 - $244,824
-1,476 Reduced 3.8%
37,359 $6.04 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $252,851 - $290,004
-1,884 Reduced 4.63%
38,835 $5.21 Million
Q2 2022

Nov 16, 2022

BUY
$137.62 - $174.96 $259,276 - $329,624
1,884 Added 4.85%
40,719 $6.24 Million
Q2 2022

Aug 01, 2022

SELL
$137.62 - $174.96 $192,255 - $244,419
-1,397 Reduced 3.32%
40,719 $6.24 Million
Q1 2022

May 02, 2022

SELL
$131.98 - $163.75 $173,685 - $215,495
-1,316 Reduced 3.03%
42,116 $6.83 Million
Q4 2021

Feb 02, 2022

BUY
$107.43 - $135.93 $246,981 - $312,503
2,299 Added 5.59%
43,432 $5.88 Million
Q3 2021

Nov 01, 2021

SELL
$106.4 - $120.78 $17,556 - $19,928
-165 Reduced 0.4%
41,133 $4.44 Million
Q2 2021

Aug 03, 2021

BUY
$105.21 - $117.21 $210,314 - $234,302
1,999 Added 5.09%
41,298 $4.65 Million
Q1 2021

Apr 22, 2021

BUY
$102.3 - $112.62 $329,610 - $362,861
3,222 Added 8.93%
39,299 $4.25 Million
Q4 2020

Feb 02, 2021

BUY
$80.49 - $108.67 $4,024 - $5,433
50 Added 0.14%
36,077 $3.87 Million
Q3 2020

Nov 03, 2020

SELL
$85.91 - $100.83 $218,726 - $256,713
-2,546 Reduced 6.6%
36,027 $3.16 Million
Q2 2020

Jul 28, 2020

SELL
$73.37 - $98.18 $346,746 - $463,998
-4,726 Reduced 10.91%
38,573 $3.79 Million
Q1 2020

Apr 24, 2020

BUY
$64.5 - $97.79 $49,471 - $75,004
767 Added 1.8%
43,299 $3.3 Million
Q4 2019

Jan 31, 2020

BUY
$72.13 - $90.25 $34,622 - $43,320
480 Added 1.14%
42,532 $3.77 Million
Q3 2019

Nov 01, 2019

BUY
$62.98 - $75.72 $92,895 - $111,687
1,475 Added 3.64%
42,052 $3.18 Million
Q2 2019

Aug 08, 2019

BUY
$65.7 - $83.98 $429,678 - $549,229
6,540 Added 19.21%
40,577 $2.95 Million
Q1 2019

May 09, 2019

BUY
$77.14 - $90.79 $209,512 - $246,585
2,716 Added 8.67%
34,037 $2.74 Million
Q4 2018

Feb 08, 2019

BUY
$77.85 - $96.01 $135,147 - $166,673
1,736 Added 5.87%
31,321 $2.89 Million
Q3 2018

Oct 26, 2018

BUY
$88.91 - $98.84 $244,502 - $271,810
2,750 Added 10.25%
29,585 $2.8 Million
Q2 2018

Aug 02, 2018

SELL
$89.78 - $106.23 $140,056 - $165,718
-1,560 Reduced 5.49%
26,835 $2.49 Million
Q1 2018

Apr 27, 2018

SELL
$92.01 - $123.21 $332,340 - $445,034
-3,612 Reduced 11.29%
28,395 $2.69 Million
Q4 2017

Jan 24, 2018

SELL
$89.56 - $98.21 $238,766 - $261,827
-2,666 Reduced 7.69%
32,007 $3.1 Million
Q3 2017

Oct 30, 2017

BUY
$69.85 - $89.22 $2.42 Million - $3.09 Million
34,673
34,673 $3.08 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hallmark Capital Management Inc Portfolio

Follow Hallmark Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hallmark Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hallmark Capital Management Inc with notifications on news.